Overview

STATEMENT OF NEED

Prostate cancer is the most common tumor type among men in the United States. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Metastatic CRPC is the primary cause of prostate-related mortality, accounting for an estimated 26,730 deaths annually. Median overall survival remains less than 2 years.

TARGET AUDIENCE

Medical oncologists, urologists, oncology advanced practitioners, oncology and urology nurses, and other health care professionals involved in the treatment of patients with castration-resistant prostate cancer.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

  • Evaluate recent study findings on combination and sequential treatment strategies for patients with metastatic CRPC
  • Determine which predictive/prognostic biomarker tests are ready for application in metastatic CRPC practice
  • Utilize strategies for evaluating treatment response, incorporating imaging studies, prostate-specific antigen levels, and clinical findings

FACULTY

Tanya Dorff, MDTanya Dorff, MD (Chairperson)
Associate Professor of Clinical Medicine
Keck School of Medicine of USC

REGISTRATION

There is no fee to participate in or claim CME credit for this activity.

Please note that the Postgraduate Institute for Medicine and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.

Jointly Provided by

  PIM Logoi3 Health Logo

ACCME Commendation LogoThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and i3 Health. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.  This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose. i3 Health planners and managers have no relevant financial relationships to disclose.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must:

  1. Participate in the live webinar
  2. Complete and submit the posttest and activity evaluation via the link provided after the webinar
  3. Download or print their Certificate of Credit

UNAPPROVED USE DISCLOSURE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

COMMERCIAL SUPPORT

This activity is supported by an independent educational grant from Bayer HealthCare Pharmaceuticals Inc. and Genzyme.

CONTACT INFORMATION

If you have technical queries about this activity or issues with your CME certificate, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.. For questions regarding the activity’s accreditation, please contact the accredited provider at This email address is being protected from spambots. You need JavaScript enabled to view it..